{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-A2HWJPWT/dad62d47-8c21-4269-8140-c69d0198d3bf/PDF","dcterms:extent":"716 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:doc-A2HWJPWT/3278fd15-bf43-40c1-9a75-316373ecdac0/TEXT","dcterms:extent":"48 KB"}],"edm:TimeSpan":{"@rdf:about":"2005-2025","edm:begin":{"@xml:lang":"en","#text":"2005"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:doc-A2HWJPWT","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN"},{"@xml:lang":"sl","#text":"Farmacevtski vestnik"}],"dcterms:issued":"2024","dc:creator":"Bratkovič, Tomaž","dc:format":[{"@xml:lang":"sl","#text":"številka:2"},{"@xml:lang":"sl","#text":"letnik:75"},{"@xml:lang":"sl","#text":"str. 120-129"}],"dc:identifier":["ISSN:0014-8229","COBISSID_HOST:196220163","URN:URN:NBN:SI:doc-A2HWJPWT"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"dc:subject":[{"@xml:lang":"sl","#text":"alemtuzumab"},{"@xml:lang":"en","#text":"anti-CD20 monoclonal antibodies"},{"@xml:lang":"sl","#text":"Biološka zdravila"},{"@xml:lang":"sl","#text":"glatiramer"},{"@xml:lang":"sl","#text":"interferon beta"},{"@xml:lang":"sl","#text":"monoklonska protitelesa proti CD20"},{"@xml:lang":"sl","#text":"Multipla skleroza"},{"@xml:lang":"en","#text":"multiple sclerosis"},{"@xml:lang":"sl","#text":"natalizumab"}],"dcterms:temporal":{"@rdf:resource":"2005-2025"},"dc:title":{"@xml:lang":"sl","#text":"Biološka zdravila za zdravljenje multiple skleroze| Biologicals for the treatment of multiple sclerosis|"},"dc:description":[{"@xml:lang":"sl","#text":"Multiple sclerosis is an incurable neurodegenerative disease, characterized by demyelination and neurodegeneration, leading to disability. With early detection and immediate continuous treatment with modern disease-modifying drugs (including biological medicines), the relapse rate and intensity can be decreased, and the accumulation of demyelinating plaques in the central nervous system diminished, thereby slowing the disease progression. In this review, we summarize the results of clinical trials evaluating efficacy and safety of biological medicines for the treatment of multiple sclerosis. In particular, monoclonal antibodies (natalizumab, alemtuzumab, ofatumumab, ocrelizumab and ublituximab) display high efficacy, but are associated with certain serious adverse effects, such as cytokine release syndrome, (opportunistic) infections and autoimmune diseases"},{"@xml:lang":"sl","#text":"Multipla skleroza je neozdravljiva nevrodegenerativna bolezen, za katero je značilna demielinizacija in propadanje nevronov, kar vodi v invalidnost. Z zgodnjim odkrivanjem in takojšnjim neprekinjenim zdrav - ljenjem s sodobnimi zdravili, med katera sodijo tudi biološka zdravila, lahko spremenimo potek bolezni – zmanjšamo pogostost in jakost zagonov ter omejimo kopičenje demielinizacijskih plakov v centralnem živčevju, s čimer upočasnimo napredovanje bolezni. V prispevku povzemamo izsledke kliničnih vrednotenj učinkovitosti in varnosti bioloških zdravil za zdravljenje multiple skleroze. Zlasti monoklonska protitelesa (natalizumab, alemtuzumab, ofatumumab, okrelizumab in ublituksimab) izkazujejo visoko učinkovitost, a jih povezujemo z nekaterimi resnimi neželenimi učinki, kot so sindrom sproščanja citokinov, (oportunistične) okužbe in avtoimunske bolezni"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:doc-A2HWJPWT","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:doc-A2HWJPWT"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:doc-A2HWJPWT/dad62d47-8c21-4269-8140-c69d0198d3bf/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:intermediateProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:dataProvider":{"@xml:lang":"sl","#text":"Slovensko farmacevtsko društvo"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:doc-A2HWJPWT/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:doc-A2HWJPWT"}}}}